Brokers Offer Predictions for KROS Q3 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Stock analysts at Wedbush issued their Q3 2024 earnings per share estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Monday, November 4th. Wedbush analyst Y. Zhong forecasts that the company will post earnings per share of ($1.31) for the quarter. Wedbush currently has a “Outperform” rating and a $84.00 target price on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The firm had revenue of $0.39 million for the quarter. During the same quarter last year, the business posted ($1.33) earnings per share. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year.

Other analysts also recently issued reports about the company. Scotiabank started coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday. They issued a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Thursday. Guggenheim initiated coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price for the company. Finally, Bank of America dropped their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $67.17 on Thursday. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The company has a market cap of $2.52 billion, a PE ratio of -13.09 and a beta of 1.23. The stock’s 50 day moving average price is $57.30 and its 200 day moving average price is $51.99.

Insider Transactions at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the transaction, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock worth $870,000 after purchasing an additional 251 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the period. KBC Group NV increased its stake in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares during the period. Arizona State Retirement System increased its stake in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after acquiring an additional 1,130 shares during the period. Finally, American International Group Inc. grew its stake in shares of Keros Therapeutics by 13.1% in the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock valued at $838,000 after purchasing an additional 1,465 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.